Tenet Healthcare Corporation (NYSE:THC) Q4 2023 Earnings Call Transcript

From a clinical standpoint, what we want to do. The competitive landscape in the ASC segment is active and intense, and I think that will certainly continue. Look, we think we have a lot of advantages based upon our scale, our physician relationships, our ability to deliver synergies, and also just the consistent, demonstrated operating excellence over a long period of time. And now we add to that what we think is a best-in-class revenue cycle capability that we’ve built inside of USPI, separate from Conifer, inside of USPI, that is starting to do work even for non USPI centers, which is an exciting development. So we’re doing a lot to innovate in that business to continue to maintain our leadership position. So I feel very good about where we are competitively there.

Sun Park: And Jamie, just on your final question. Yes, there was no impact from a surgical day basis on our growth in Q4. It was 3.9% overall case growth.

Jamie Perse: Okay, great. Thank you.

Operator: Thank you. And we have reached the end of the question-and-answer session, and this also concludes today’s conference. You may disconnect your lines at this time. Thank you for your participation.